While therapies such as ARNI, SGLT2 inhibitors, and MRAs have individually shown benefits in improving hemodynamics and reducing neurohormonal activation, their combined effects on the neuroendocrine mechanisms in heart failure have not been well explored. Here, SLC5A2 is linked to heart failure.